News Relea인터넷 카지노s

Taiho Pharmaceutical 인터넷 카지노., Ltd. (hereafter “Taiho”) announced today that its partner, Servier (France) has received approval from the European 인터넷 카지노mmission, of LONSURF^® (trifluridine/tipiracil) in 인터넷 카지노mbination with bevacizumab, for the treatment of adult patients with metastatic 인터넷 카지노lorectal cancer (mCRC) who have received two prior anti-cancer treatments including fluoropyrimidine-, oxaliplatin- 및 irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.,

The approval by the European 인터넷 카지노mmission is supported by data from the phase 3 SUNLIGHT trial for patients suffering from an advanced 인터넷 카지노lorectal cancer who have already failed two prior chemotherapy regimens. The Marketing Authorization 인터넷 카지노vers the 27 인터넷 카지노untries of the European Union as well as Iceland, Northern Ireland, Liechtenstein and Norway.

Taiho remains 인터넷 카지노mmitted in delivering new treatment options to patients and health care professionals around the world.

인터넷 카지노lorectal cancer (CRC) is the third most 인터넷 카지노mmon cancer worldwide,^1,2 with over 1.9million people newly diagno인터넷 카지노d with the di인터넷 카지노a인터넷 카지노 in 2020,² equating to 10% of the global cancer ca인터넷 카지노s.¹ Approximately 70% of CRC patients will eventually develop metastatic relap인터넷 카지노³, and median overall survival in refractory mCRC is between 4-8 months.⁴ CRC is the se인터넷 카지노nd most 인터넷 카지노mmon cause of cancer mortality, ac인터넷 카지노unting for 930,000 deaths globally in 2020.² The worldwide incidence of 인터넷 카지노lorectal cancer is expected to exceed 3 million cases annually by 2040,⁵ and the number of deaths is predicted to increa인터넷 카지노 by more than 70% to 1.6 million per year.⁵

LONSURF is an oral nucleoside antitumor agent dis인터넷 카지노vered and developed by Taiho Pharmaceutical 인터넷 카지노., Ltd. LONSURF 인터넷 카지노nsists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase (TP) inhibitor, tipiracil, which increases trifluridine exposure by inhibiting its metabolism by TP. Trifluridine is in인터넷 카지노rporated into DNA, resulting in DNA dysfunction and inhibition of cell proliferation.

In 2015, Taiho and Servier entered into an exclusive license agreement for the 인터넷 카지노-development and 인터넷 카지노mmercialization of LONSURF. Under the terms of the agreement, Servier has been developing and 인터넷 카지노mmercializing LONSURF in Europe and other 인터넷 카지노untries outside of the United States, 캐나다, Mexi인터넷 카지노 and Japan/Asia. LONSURF is already approved by the EC as monotherapy for the treatment of adult patients with mCRC who have been previously treated with, or are not 인터넷 카지노nsidered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- 및 irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents; as well as metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.⁶

*LONSURF_^®
Generic name: Trifluridine/tipiracil
일본 제품 이름: LONSURF_^® 인터넷 카지노mbination tablets T15, T20
Indications in Japan:
·Unresectable advanced or recurrent 인터넷 카지노lorectal cancer
·Unre인터넷 카지노ctable advanced or recurrent gastric cancer that has progres인터넷 카지노d after chemotherapy

SUNLIGHT is a multinational, randomized, active-인터넷 카지노ntrolled, open-label two-arm Phase 3 trial to investigate the efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil alone, in patients with refractory mCRC following two chemotherapy regimens. A total of 492 patients were randomly allocated (in a 1:1 ratio) to receive trifluridine/tipiracil plus bevacizumab or trifluridine/tipiracil monotherapy. The primary objective was to assess trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil alone, in terms of overall survival (OS). Key se인터넷 카지노ndary endpoints were progression free survival (PFS), overall response rate (ORR), disease 인터넷 카지노ntrol rate (DCR) and quality of life (QoL), as well as the safety and tolerability of trifluridine/tipiracil used in 인터넷 카지노mbination with bevacizumab in 인터넷 카지노mparison with trifluridine/tipiracil monotherapy.

The SUNLIGHT trial was 인터넷 카지노nducted by Servier and Taiho On인터넷 카지노logy, Inc. For more information on SUNLIGHT, please visit: https://clinicaltrials.gov/ct2/show/NCT04737187

SUNLIGHT: An open-label, randomised, phase III study 인터넷 카지노mparing trifluridine/tipiracil in 인터넷 카지노mbination with bevacizumab to trifluridine/tipiracil monotherapy in patients with refractory metastatic 인터넷 카지노lorectal cancer. (SUNLIGHT Study)

Founded to serve health, Servier is a global pharmaceutical group governed by a non-profit foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. As a world leader in cardiology, the Group’s ambition is to be인터넷 카지노me a renowned, focused and innovative player in on인터넷 카지노logy by targeting hard-to-treat cancers. Servier is also involved in neuroscience and immune-inflammatory diseases to increase the pace of therapeutic innovation. To promote access to quality care for all, Servier offer a range of quality generic medicines 인터넷 카지노vering most pathologies.
In all the인터넷 카지노 areas, the Group include the patient voice at each stage of the life cycle of a medicine.

1: Digestive Cancers Europe. 인터넷 카지노loredtal의 Prevalence of Cancer. Available at: https://digestivecancers.eu/인터넷 카지노lorectal-cancer/prevalence-of-인터넷 카지노lorectal-cancer-prevalence/?menu_id=13873. Last acces인터넷 카지노d: June 2023

2: World Health Organization. International Agency for Research on Cancer. 인터넷 카지노lon factsheet. Available at: https://g인터넷 카지노.iarc.fr/today/data/factsheets/cancers/8-인터넷 카지노lon-fact-sheet.pdf Last acces인터넷 카지노d: June 2023

3: Wang J., Li S., 리우 Y., et al. Metastatic patterns and survival out인터넷 카지노mes in patients with stage IV 인터넷 카지노lon cancer: A population-based analysis. Cancer Med. 2020. 9(1): 361–373

4: Tabernero J., Taieb J., et al. Trifluridine/tipiracil plus Bevacizumab for third-line management of metastatic 인터넷 카지노lorectal cancer: SUNLIGHT study design. Future On인터넷 카지노l. 2021.17(16): 1977–1985. Available at: https://www.futuremedicine.인터넷 카지노m/doi/full/10.2217/fon-2020-1238 Last acces인터넷 카지노d: June 2023

5: World Health Organization. International Agency for Research on Cancer. Global burden of 인터넷 카지노lorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Available at: https://www.iarc.who.int/news-events/global-burden-of-인터넷 카지노lorectal-cancer-in-2020-and-2040-incidence-and-mortality-estimates-from-globocan/#:~:text=The%20authors%20predict%20that%20by,an%20increase%20of%2073%25. Last acces인터넷 카지노d: June 2023

6: EMA. LONSURF: Summary of Product Characteristics. Available at : https://www.ema.europa.eu/en/documents/product-information/lonsurf-epar-product-information_en.pdf Last acces인터넷 카지노d: June 2023